SHANGHAI FUDAN H YC-,10 Market Cap ($100.96 Million)
Market Cap & Net Worth: SHANGHAI FUDAN H YC-,10 (FDY)
SHANGHAI FUDAN H YC-,10 market cap. SHANGHAI FUDAN H YC-,10 (F:FDY) has a market capitalization of $100.96 Million (€86.36 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #18977 globally and #1749 in its home market, demonstrating a -4.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANGHAI FUDAN H YC-,10's stock price €0.25 by its total outstanding shares 340000000 (340.00 Million). Also see cash efficiency ratio of SHANGHAI FUDAN H YC-,10 for how efficiently the company converts equity into cash flow.
SHANGHAI FUDAN H YC-,10 Market Cap History (2020–2026)
SHANGHAI FUDAN H YC-,10 market cap history from 2020 to 2026. Data shows growth from $43.80 Million to $100.96 Million (14.72% CAGR). Check SHANGHAI FUDAN H YC-,10 (FDY) share price today for real-time trading data and today's change.
SHANGHAI FUDAN H YC-,10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANGHAI FUDAN H YC-,10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SHANGHAI FUDAN H YC-,10 equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.18x
SHANGHAI FUDAN H YC-,10's market cap is 0.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $55.37 Million | $1.14 Billion | $213.30 Million | 0.05x | 0.26x |
| 2022 | $68.89 Million | $1.03 Billion | $138.00 Million | 0.07x | 0.50x |
| 2023 | $63.16 Million | $850.73 Million | $108.63 Million | 0.07x | 0.58x |
| 2024 | $117.66 Million | $709.40 Million | $39.73 Million | 0.17x | 2.96x |
| 2025 | $123.22 Million | $685.80 Million | -$157.44 Million | 0.18x | N/A |
Competitor Companies of FDY by Market Capitalization
Companies near SHANGHAI FUDAN H YC-,10 in the global market cap rankings as of November 4, 2026. Also see FDY total assets for a full breakdown of the balance sheet.
Key companies related to SHANGHAI FUDAN H YC-,10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of SHANGHAI FUDAN H YC-,10 (2020–2026)
Market capitalization of SHANGHAI FUDAN H YC-,10 from 2020 to today. Between 2020 and today, SHANGHAI FUDAN H YC-,10's market cap moved from $43.80 Million to $ 100.96 Million, with a yearly change of 14.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €100.96 Million | -18.06% |
| 2025 | €123.22 Million | +4.73% |
| 2024 | €117.66 Million | +86.28% |
| 2023 | €63.16 Million | -8.31% |
| 2022 | €68.89 Million | +24.41% |
| 2021 | €55.37 Million | +26.41% |
| 2020 | €43.80 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of SHANGHAI FUDAN H YC-,10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $100.96 Million USD |
| MoneyControl | $100.96 Million USD |
| MarketWatch | $100.96 Million USD |
| marketcap.company | $100.96 Million USD |
| Reuters | $100.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more